
This ‘optimal use’ project from the Canadian Agency for Drugs and Technologies in Health assesses the clinical and economic impact of using atypical antipsychotic combination therapy, as well as high-dosing treatment strategies, in adolescents and adults with schizophrenia. The report was produced by an expert panel who based their recommendations on a systematic review and [read the full story…]